Form 4: Contineum Therapeutics Director Lori Lyons-Williams Granted Stock Options

Director Lori Lyons-Williams received 29,500 stock options in Contineum Therapeutics, Inc. on May 24, 2024, under the company's 2024 Equity Incentive Plan.

Summary

• Lori Lyons-Williams, a director of Contineum Therapeutics, Inc. (CTNM), was granted 29,500 stock options on May 24, 2024.
• The options were granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended.
• The exercise price of the options is $15.76 per share.
• One-third of the option shares vest on April 5, 2025, with the remainder vesting in 24 equal monthly installments thereafter, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice (option grant) and doesn't contain any alarming or negative information. It's a neutral event with a slightly positive implication for aligning director incentives.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors, aligning their interests with the long-term performance of the company. This grant is part of Contineum Therapeutics' Non-Employee Director Compensation Program.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice in the biotechnology industry.
• The size of the grant and the vesting schedule are typical for companies of Contineum Therapeutics' size and stage of development.
• Comparable companies such as Annexon Biosciences (ANNX) and Biohaven Pharmaceutical Holding Company (BHVN) also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns the director's interests with the company's long-term success.
• The director benefits from the potential future value of the options.

Key Dates